Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

NCT ID: NCT05469360

Last Updated: 2025-08-28

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-23
• Study Completion Date: 2028-01-02

Brief Summary

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)

Detailed Description

This is a phase 1b, randomized, double-blind, placebo-controlled study, in which 36 patients with early AD will be enrolled in one of three cohorts.

Cohorts 1 & 2 will receive a single intrathecal (IT) dose of NIO752 or placebo in the placebo-controlled part of the study, and multiple administrations of NIO752 in the open-label extension (OLE) part of the study.

Cohort 3 will receive two single IT doses of NIO752 or placebo in the placebo-controlled part of the study, and a single administration of NIO752 in the OLE part of the study.

Each cohort will enroll 12 participants, and they will be randomized into receiving NIO752 or placebo in 2:1 ratio. Participants in cohorts 1& 2 will remain in this study for approximately ~19 months, including ~18 in-clinic follow up visits during that period of time. In cohort 3, participants will remain in this study for a follow up period of approximately ~18 months including ~10 in-clinic follow up visits.

Cohorts will be enrolled sequentially.

Participants who complete the placebo-controlled part of the study will be eligible to continue in an OLE part of the study regardless of randomization assignment in the placebo-controlled part. All OLE participants will receive either two (cohorts 1 & 2) or one (cohort 3) dose of NIO752.

Study assessments will include physical and neurological examinations, ECGs, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, and urinalysis), routine laboratory evaluation of CSF collected through lumbar puncture, adverse event, and serious adverse event monitoring. Cohort 3 participation will also require 3 MRI scans and 3 PET scans throughout the 18 months of the study.

Conditions

Alzheimer Disease; Mild Cognitive Impairment

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

NIO752 - Dose A - Cohort 1

A single intrathecal injection of Dose A

Group Type: EXPERIMENTAL

NIO752

Intervention Type: DRUG

A single intrathecal (cerebrospinal) injection of NIO752 of Dose A

Matching placebo - Cohort 1

A single intrathecal injection of artificial cerebrospinal fluid (CSF)

Group Type: PLACEBO_COMPARATOR

Matching placebo

Intervention Type: DRUG

A single intrathecal injection of matching placebo

NIO752 Dose B - Cohort 2

A single intrathecal injection of Dose B

Group Type: EXPERIMENTAL

NIO752

Intervention Type: DRUG

A single intrathecal (cerebrospinal) injection of NIO752 at dose B

Matching placebo - Cohort 2

A single intrathecal injection of artificial cerebrospinal fluid (CSF)

Group Type: PLACEBO_COMPARATOR

Matching placebo

Intervention Type: DRUG

A single intrathecal injection of matching placebo

NIO752 OLE - Cohorts 1 and 2

Multiple intrathecal injections of Dose A

Group Type: EXPERIMENTAL

NIO752

Intervention Type: DRUG

Multiple intrathecal injections of NIO752 of Dose A

NIO752 - Dose C - Cohort 3

Two intrathecal injections of Dose C

Group Type: EXPERIMENTAL

NIO752

Intervention Type: DRUG

Two intrathecal injections of NIO752 at dose C

Matching Placebo - Cohort 3

Two intrathecal injections of artificial cerebrospinal fluid (CSF)

Group Type: PLACEBO_COMPARATOR

Matching placebo

Intervention Type: DRUG

Two intrathecal injections of matching placebo

NIO752 OLE - Cohort 3

Single intrathecal injection of Dose C

Group Type: EXPERIMENTAL

NIO752

Intervention Type: DRUG

Single intrathecal injection of NIO752 at dose C

Interventions

NIO752

A single intrathecal (cerebrospinal) injection of NIO752 of Dose A

Intervention Type: DRUG

NIO752

A single intrathecal (cerebrospinal) injection of NIO752 at dose B

Intervention Type: DRUG

Matching placebo

A single intrathecal injection of matching placebo

Intervention Type: DRUG

NIO752

Multiple intrathecal injections of NIO752 of Dose A

Intervention Type: DRUG

NIO752

Two intrathecal injections of NIO752 at dose C

Intervention Type: DRUG

NIO752

Single intrathecal injection of NIO752 at dose C

Intervention Type: DRUG

Matching placebo

Two intrathecal injections of matching placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Between 30 to 74 years old (both inclusive) at the time of informed consent.
• A diagnosis of mild Alzheimer's Disease (AD) or mild cognitive impairment (MCI) due to AD at screening with at least a 6-month decline in cognitive function prior to screening documented in the medical record. Both participants with sporadic AD as well as Amyloid Precursor Protein (APP), Presenilin-1 (PSEN1) or Presenilin-2 (PSEN2) mutation carriers are eligible.
• Participants must have a diagnosis of MCI due to AD or mild AD at screening as defined by a Clinical Dementia Rating Scale (CDR) Global Score of 0.5 or 1 and a Memory Score ≥ 0.5.
• A history of CSF biomarkers supporting the diagnosis of AD obtained at any time point prior to screening, including CSF amyloid (amyloid-β 42 and/or 42/40 ratio) AND tau species (total tau and/or phosphorylated tau). All participants must have documented historical confirmation of both CSF biomarkers (amyloid-β and tau species) with results supporting a diagnosis of AD prior to screening. This criterion will be determined individually for each participant taking into consideration the biomarker assay used in each case. For participants (Cohorts 1 & 2 only) with no historical CSF biomarker information, a LP for CSF collection must be performed at the screening visit. For CSF collected at screening, participants must have confirmed positivity of amyloid-β-42 ≤ 1000 pg/mL as well as positivity on, at least, one of the following Tau biomarkers: phosphorylated-tau-181 > 12 pg/ml OR T-tau > 149.9 pg/mL as determined by the central laboratory.
• Participant has a reliable study partner or caregiver (e.g., spouse, sibling, close friend, adult child) who, is at least 18 years old.
• Participant resides in a proximity to the study site to allow a timely unscheduled visit to the study site, if necessary.
• Participant is able to undergo lumbar puncture (LP), CSF collections, and blood draws, tolerate brain MRI and PET scanning, and able to participate and tolerate all study procedures at study visit.

• Signed informed consent of protocol version inclusive of the OLE.
• Participant must complete Day 170 of the placebo-controlled part of this study.

Exclusion Criteria

• Participant lives in a skilled nursing facility or dementia care facility.
• Any previous use of experimental therapy within 180 days or 5 half-lives prior to Day 1, whichever is greater. Previous exposure to anti-tau and anti-β-amyloid antibodies is allowed if at the time of screening at least 180 days have passed since the last dose. Previous exposure to amyloid vaccines or tau vaccines meant to treat AD, or previous treatment with oligonucleotides or with gene therapy at any time frame is not allowed.
• Any current or past non-AD neurological conditions.
• Other medical conditions including but not limited to poorly controlled diabetes mellitus, unstable angina, myocardial infarction, chronic heart failure, clinical significant conduction abnormalities, impaired renal or kidney function, which, in the opinion of the Investigator, would make the participant unsuitable for inclusion or could interfere with the participation in or completion of the study.
• Treatment with immunosuppressants, antipsychotics, lithium, neuroleptics, dopaminergic agonists, L-dopa, or monoamine oxidase inhibitors at the time of screening. Current use of medications, other than cholinesterase inhibitors and/or memantine, that could alter cognition, as determined by the Investigator. If the participant is receiving cholinesterase inhibitors and/or memantine, the dose must have been stable within 12 weeks prior to screening, and must remain stable during the duration of the study.
• Brain MRI at screening or within 12 months prior to screening showing evidence of cerebrovascular disease such as acute or sub-acute micro- or macrohemorrhage, significant signs of major cerebrovascular disease, or any other imaging evidence that, in the opinion of the Investigator, makes the participant unsuitable for the study.

• Use of any investigational drugs, or participation in a clinical trial with an investigational new drug (other than NIO752), after completing the initial placebo-controlled part of this trial
• Participants who withdrew informed consent while participating in the main placebo-controlled part of the study

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 74 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Madhav Thambisetty, MD PhD

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Novartis Investigative Site

Kuopio, , Finland

Site Status: COMPLETED

Novartis Investigative Site

Turku, , Finland

Site Status: COMPLETED

Novartis Investigative Site

Lille, , France

Site Status: RECRUITING

Novartis Investigative Site

Paris, , France

Site Status: RECRUITING

Novartis Investigative Site

Toulouse, , France

Site Status: RECRUITING

Novartis Investigative Site

Valencia, Valencia, Spain

Site Status: RECRUITING

Novartis Investigative Site

Barcelona, , Spain

Site Status: RECRUITING

Novartis Investigative Site

Barcelona, , Spain

Site Status: RECRUITING

Novartis Investigative Site

Malmo, , Sweden

Site Status: COMPLETED

Novartis Investigative Site

Stockholm, , Sweden

Site Status: COMPLETED

Countries

Finland; France; Spain; Sweden

Central Contacts

Novartis Pharmaceuticals

Role: CONTACT

novartis.email@novartis.com

+41613241111

Novartis Pharmaceuticals

Role: CONTACT

Other Identifiers

2024-514004-14

Identifier Type: OTHER

Identifier Source: secondary_id

CNIO752B12201

Identifier Type: -

Identifier Source: org_study_id